Summary

Overview
Global Gastroparesis Drugs Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031
Gastroparesis or delayed gastric emptying, is a disorder that disrupts the movement of food from the stomach to the small intestine. Normally, the stomach's muscles grind food into smaller pieces for digestion. In gastroparesis, these muscles are weak or absent, causing the stomach to take too long to empty its contents, leading to various symptoms and complications.
Market Dynamics: Drivers & Restraints
Rise in the prevalence of gastroparesis
The increasing prevalence of gastroparesis, often associated with conditions like diabetes, neurological disorders, and post-surgical complications, has fueled the demand for effective treatments. As awareness about the condition grows, there's a greater focus on developing novel therapies. For instance, in an epidemiologic study from Europe, the estimated overall prevalence of gastroparesis was 13.8 per 100,000 persons with an incidence of 1.9 per 100,000 person-years.
Moreover, in U.S 71,775 patients with gastroparesis with a prevalence of 268 per 100,000 persons, with the highest prevalence among those aged between 58 and 64 years. The prevalence of diabetic gastroparesis was 4 times that of idiopathic gastroparesis. Only 36% of the cohort classified as having gastroparesis underwent GES testing before the index date, and the remaining 64% were identified through diagnostic codes.
Furthermore, global gastroparesis drugs are also driven by various other factors like advancements in research and development, emerging therapeutic targets and others helping the market to grow during the forecast period.
Adverse effects and safety concerns
Pharmacological treatments for gastroparesis, like prokinetic agents and antiemetics, have adverse effects like extrapyramidal symptoms and cardiac arrhythmias. Safety concerns and potential complications may deter patients and healthcare providers from using these medications as primary treatments. Similarly, surgical interventions and implantable devices carry risks, impacting their adoption and utilisation in clinical practice. These factors are expected to hinder market growth.
Segment Analysis
The global gastroparesis drugs market is segmented based on drug type, disease type, end-user and region.
The prokinetic agents from the drug type segment accounted for approximately 42.3% of the Gastroparesis Drugs market share
The prokinetic agents from the drug type segment accounted for approximately 42.3%. Prokinetic agents are medications that enhance coordinated gastrointestinal motility and transit of content in the gastrointestinal tract, mainly by amplifying and coordinating gastrointestinal muscular contractions. In addition to dietary therapy, prokinetic therapy should be considered as a means to improve gastric emptying and symptoms of gastroparesis, balancing the benefits and risks of treatment.
For instance, in February 2023, Renexxion Ireland Limited, a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, is pleased to announce that the first patient has been treated in Europe with naronapride, a potential best-in-class pan-GI prokinetic, in a Phase IIb trial for gastroparesis conducted by Dr Falk Pharma GmbH.
Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the rising number of diabetes cases, which is more prevalent in this region. Additionally, a substantial prediabetic population, favorable reimbursement policies, and increasing awareness about the condition further contribute to the growing incidence of gastroparesis.
According to the CDC's June 2022, report, an estimated 96 million adults aged 18 and older have prediabetes, encompassing 38.0% of the entire U.S. adult population. North America's advanced healthcare infrastructure and increasing pharmaceutical industry are important in supporting the development, accessibility, and distribution of gastroparesis medications.
Moreover, in July 2022, Evoke Pharma, Inc., a speciality pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray for diabetic gastroparesis, announced that the Canadian Intellectual Property Office granted the company a key patent for its previously submitted application. The received patent is for GIMOTI's method of use.
Covid 19 Impact Analysis
In patients with chronic gastrointestinal illnesses, COVID-19 initially created a lot of complications as viruses have historically been implicated in complications of gastrointestinal disorders, including gastroparesis. According to an article published by PubMed Central in March 2022, patients suffering from COVID-19 can present with a variety of GI symptoms, such as diarrhoea, anorexia, nausea, and vomiting, and can be associated with several GI conditions such as liver injury, GI bleeding, acute cholecystitis, and acute pancreatitis among others.
Market Segmentation
By Drug Type
• Prokinetic Agents
o Metoclopramide
o Erythromycin
o Others
• Antiemetic Agents
o Ondansetron
o Granisetron
o Prochlorperazine
• Antianxiety Agents
• Botulinum Toxin Injections
• Others
By Disease Type
• Diabetic Gastroparesis
• Idiopathic Gastroparesis
• Postsurgical Gastroparesis
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Aeromatic Healthcare, AstraZeneca Plc, Cadila Pharmaceuticals Ltd, Evoke Pharma, Neurogastrx, Inc., Teva Pharmaceutical Industries among others.
Key Developments
 In August 2022, Processa Pharmaceuticals, Inc. initiated its Phase 2A clinical trial for PCS12852, enrolling its first patient with moderate to severe gastroparesis.
 In February 2022, Vanda Pharmaceuticals Inc. (Vanda) shared the Phase III clinical trial outcomes, VP-VLY-686-3303, revealing the effectiveness and safety of precipitant in addressing gastroparesis symptoms.
Why Purchase the Report?
• To visualise the global gastroparesis drugs market segmentation based on drug type, disease type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of the gastroparesis drugs market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global gastroparesis drugs market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Disease Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of gastroparesis
4.1.1.2. Rise of advancements in research and development
4.1.2. Restraints
4.1.2.1. Adverse effects and safety concerns
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Prokinetic Agents *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Antiemetic Agents
7.4. Antianxiety Agents
7.5. Botulinum Toxin Injections
7.6. Others
8. By Disease Type
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.1.2. Market Attractiveness Index, By Disease Type
8.2. Diabetic Gastroparesis*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Idiopathic Gastroparesis
8.4. Postsurgical Gastroparesis
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Aeromatic Healthcare*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. AstraZeneca Plc
12.3. Cadila Pharmaceuticals Ltd.
12.4. Evoke Pharma
12.5. Neurogastrx, Inc.
12.6. Teva Pharmaceutical Industries
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us